Alnylam Pharmaceuticals Inc
ALNY: XNAS (USA)
Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
---|---|---|---|
$886.00 | Wcqfgm | Kmngtnb |
Narrow-Moat Alnylam Reports Strong Q4 Results; We Maintain $199 FVE and See Shares as Fairly Valued
Alnylam Pharmaceuticals reported solid fourth-quarter and full-year results highlighted by $894 million in global net product revenue in 2022, representing 35% growth over 2021. Alnylam’s results are largely tracking our forecasts, and we maintain our $199 fair value estimate. The stock is currently trading in 3-star territory, about 5% below our fair value estimate. We maintain our narrow economic moat rating and positive moat trend rating as well.